Additional file 5 of Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
Creators: name: Berger, Karoline
name: Rhost, Sara
name: Svanheiður Rafnsdóttir
name: Éamon Hughes
name: Magnusson, Ylva
name: Ekholm, Maria
name: Stål, Olle
name: Rydén, Lisa
name: Landberg, Göran
Publisher: name: figshare
Year: 2021
Subjects: subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Pharmacology
subject: Biotechnology
subject: 69999 Biological Sciences not elsewhere classified
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: FOS: Mathematics
subject: Cancer
subject: Plant Biology

description: Additional file 5: Supplementary material. Fig. S1: CONSORT diagram for the study. Flowchart of the study showing the enrollment of the patients, treatment allocation and analysis. Fig. S2: ERα positive patients stratified by treatment arm. Kaplan-Meier estimates showing breast cancer-specific survival in ERα positive breast cancer patients treated with tamoxifen or randomized untreated. Fig. S3: Patients with high tumor co-expression of progranulin and sortilin have worse breast cancer-specific survival. Kaplan-Meier curves illustrating breast cancer-specific survival on combined progranulin and sortilin expression, showing high expression of both markers against all other combinations for all patients. Fig. S4: Patients with high tumor co-expression of progranulin and sortilin have worse breast cancer-specific survival in the ERα positive patient group treated with tamoxifen. Kaplan-Meier estimates showing breast cancer-specific survival on combined progranulin and sortilin expression, showing high expression of both markers against all other combinations in ERα positive breast cancer patients treated with tamoxifen. Table S1: Distribution of progranulin scores according to clinicopathological parameters in the cohort. Statistics on progranulin scoring in relation to clinical parameters. Table S2: Distribution of sortilin expression according to clinicopathological parameters in the cohort. Statistics on sortilin scoring in relation to clinical parameters. Table S3: Cross table. The relationship between progranulin and sortilin expression in the patient cohort. Table S4: Cox regression analysis on randomized untreated patients with high progranulin tumor tissue expression. Multivariable interaction analysis on breast cancer-specific survival evaluating various prognostic parameters for relative risk estimation for the untreated patient cohort having high tumor expression of progranulin. Table S5: Cox regression analysis on all patients. Univariate and multivariable interaction analysis on breast cancer-specific survival evaluating various prognostic parameters for relative risk estimation for all patients in the cohort. Table S6: Distribution of co-expression of progranulin and sortilin according to clinicopathological parameters in the cohort. Statistics on co-expression of progranulin and sortilin scoring in relation to clinical parameters. Table S7: Cox regression analysis on ERα positive patients. Multivariable regression analysis on breast cancer-specific survival evaluating various prognostic parameters for relative risk estimation for the ERα positive patient cohort.